Regeneron Pharmaceuticals stock (US75811P1003): Biotech leader in eye and oncology treatments

Regeneron Pharmaceuticals continues to drive innovation in ophthalmology and oncology with Eylea and Dupixent, key revenue generators amid strong US market demand for biologics.

Regeneron Pharmaceuticals, a leading biotechnology firm, reported robust demand for its flagship products Eylea and Dupixent in recent quarters. The company's portfolio spans ophthalmology, oncology, and immunology, with significant exposure to the US healthcare market. Eylea, approved for retinal diseases, generated substantial sales, while collaborations bolster growth.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Regeneron Pharmaceuticals, Inc.
• Sector/industry: Biotechnology
• Headquarters/country: Tarrytown, New York, USA
• Core markets: US, Europe
• Key revenue drivers: Eylea, Dupixent, Libtayo
• Home exchange/listing venue: Nasdaq (REGN)
• Trading currency: USD

Regeneron Pharmaceuticals: core business model

Regeneron Pharmaceuticals develops and commercializes medicines for serious diseases using its proprietary VelociSuite technologies, including VelocImmune for antibody discovery. The company focuses on high-unmet-need areas like eye diseases, cancer, and allergic conditions. Its business model emphasizes internal R&D alongside strategic partnerships, notably with Sanofi for Dupixent.

Founded in 1988, Regeneron has built a pipeline of over 30 investigational candidates. The firm's TRAP technology accelerates protein engineering, supporting rapid development. US investors value its Nasdaq listing and strong intellectual property portfolio.

Main revenue and product drivers for Regeneron Pharmaceuticals

Eylea, an anti-VEGF therapy for wet age-related macular degeneration and diabetic retinopathy, remains a top revenue driver. In Q4 2024 results published February 4, 2025, Eylea net sales reached $1.5 billion for the quarter, per Regeneron IR as of 02/04/2025. High-dose Eylea HD also gained traction.

Dupixent, co-developed with Sanofi, targets atopic dermatitis, asthma, and COPD. Regeneron's share of global Dupixent sales hit $851 million in Q4 2024, according to the same report. Oncology products like Libtayo contributed $241 million, reflecting expansion in immuno-oncology.

Industry trends and competitive position

The biotech sector sees rising demand for biologics amid aging US populations driving ophthalmology needs. Regeneron competes with Roche's Lucentis in eye care and Bristol Myers Squibb in oncology. Its trap-fusion proteins offer differentiation, per industry analyses from EvaluatePharma as of 2024.

Regeneron's US-centric revenue, over 70% from domestic sales, aligns with investor interest in healthcare spending under Medicare and private insurance.

Why Regeneron Pharmaceuticals matters for US investors

Listed on Nasdaq, Regeneron benefits from US FDA approvals and reimbursement dynamics. Its products address prevalent conditions like macular degeneration, affecting millions of Americans. Strong cash position supports R&D, appealing to growth-oriented portfolios.

Conclusion

Regeneron Pharmaceuticals maintains a solid position in biotech with proven products like Eylea and Dupixent driving revenue. Ongoing pipeline advancements and partnerships position it amid evolving healthcare trends. Investors track quarterly updates and regulatory milestones for insights into performance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.